Market Access · HTA · Value to Health

We help healthcare innovations reach patients.

We provide comprehensive Market Access and HTA support for the Czech and Slovak markets – from strategy and complete submission documentation to payer negotiations.

Our Services Let’s discuss your project ↗

Our Services

From strategy to sustainable reimbursement

We combine clinical evidence, health economics and in-depth knowledge of the local environment into one coherent market access solution.

Comprehensive support throughout SÚKL reimbursement proceedings

We guide you through the entire administrative process – from project feasibility and the application itself to the clinical and pharmacoeconomic sections of the Structured Submission, responses to calls for additional information, assessment reports and payer negotiations.

Pharmacoeconomics

We adapt and customise global cost-utility models to local requirements, transparently reference or validate all model inputs with local experts, and develop our own budget impact analyses.

Portfolio market access

We provide long-term market access support and monitoring for a company’s complete portfolio in the Czech Republic and Slovakia.

Strategy and negotiations

We develop reimbursement strategies and analytical materials for direct negotiations with health insurance funds.

Innovative reimbursement schemes

We design innovative performance-based reimbursement schemes that link payment to treatment outcomes observed in real-world clinical practice.

Medical devices

We develop economic models tailored to the specific requirements of the medical device reimbursement process, with a particular focus on payer budget impact analyses, and provide market access support throughout the entire process.

Expertise

Expertise in areas where every detail matters.

We understand the specific requirements of highly innovative medicinal products (VILP), rare diseases (LPVO) and preventive programmes.

VILP

We assess whether the VILP criteria are met and evaluate all risks associated with temporary reimbursement. We also develop strategies for the transition to permanent reimbursement.

Oncology

We use epidemiological data linked to local disease registries and place particular emphasis on clinical evidence, indirect comparisons, relevant extrapolations and modelled survival.

LPVO

We collect, evaluate and incorporate into the cost-utility model evidence on the broader societal value and unmet need associated with the disease, which forms the basis of the LPVO assessment.

Vaccines

We adapt population models using relevant national epidemiological data, with a strong focus on public health, herd protection and the broader societal perspective.

About Us

A partner who understands both the detail and the entire process.

PharMAHTA is a specialised consultancy focused on market access and health technology assessment in the Czech Republic and Slovakia.

We provide clients with comprehensive support in bringing pharmaceuticals and medical devices into the reimbursement system – from strategy development, HTA documentation and pharmacoeconomic analyses to payer negotiations and long-term market access support across the product portfolio.

How We Work

Five principles guiding our collaboration

Every deliverable is built on traceable sources, consistent data and a solution designed to withstand regulatory assessment and discussions with healthcare authorities and payers.